Overview
India has achieved a major public health milestone with the approval of its first dengue vaccine, QDENGA (also known as TAK-003). The vaccine has been granted marketing authorisation by the Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare. This approval assumes significant importance given India's position among countries with the world's highest dengue burden.
About QDENGA Vaccine
Developer and Manufacturer
- Developed by: Takeda Pharmaceutical Company
- Manufactured by: Takeda GmbH, Germany
- Imported by: Takeda Biopharmaceuticals India
Regulatory Approval
- Granting Authority: Central Drugs Standard Control Organisation (CDSCO)
- Legal Framework: Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945
- Basis: Comprehensive scientific and regulatory assessment of quality, safety, and efficacy
Key Features
| Feature | Details |
|---|---|
| Vaccine Type | Recombinant, live-attenuated, tetravalent |
| Age Eligibility | 4 to 60 years |
| Prior Infection Test | Not required |
| Protection | All four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4) |
Unique Advantage
Unlike certain earlier dengue vaccines, QDENGA does not require blood testing to confirm previous dengue infection before administration, making it significantly easier to deploy across eligible populations.
Global Status
- Approved in more than 40 countries
- WHO prequalified vaccine
- Over 32 million doses distributed globally
About Dengue Disease
Causative Agent
- Disease: Dengue
- Causative Virus: Dengue virus (Genus: Flavivirus)
- Vector: Female mosquito of genus Aedes, principally Aedes aegypti
Other Diseases Transmitted by Aedes Mosquito
- Chikungunya
- Yellow fever
- Zika infection
Virus Serotypes
Dengue exists in 4 distinct but closely related serotypes:
- DEN-1
- DEN-2
- DEN-3
- DEN-4
Symptoms
- Sudden high fever
- Severe headaches
- Pain behind the eyes
- Severe bone, joint, and muscle pain
Global Burden
- Estimated annual infections: 39 crore globally
- Symptomatic cases: Approximately 9.6 crore per year
- According to WHO, dengue incidence has surged globally in recent decades with many cases going unreported
Significance for India
Rising Disease Burden
Reported dengue cases in India have:
- Risen nearly 11-fold over the past two decades
- Driven by multiple factors:
- Urbanisation
- Climate change
- Population growth
- Expanding mosquito habitats
Policy Implications
- Strengthens India's Universal Immunisation Programme framework
- Demonstrates effective pharmaceutical regulatory framework under CDSCO
- Aligns with national health security objectives
- Reduces healthcare burden from dengue-related hospitalisations
Constitutional/ Legal Provisions
- Drugs and Cosmetics Act, 1940: Primary legislation governing import, manufacture, and distribution of drugs in India
- Drugs Rules, 1945: Delegated legislation providing operational framework for drug regulation
- CDSCO: Statutory body under the Ministry of Health and Family Welfare responsible for regulatory approvals
Key Takeaways for Exam Preparation
- First dengue vaccine in India: QDENGA (TAK-003)
- Regulatory body: CDSCO under Ministry of Health and Family Welfare
- Legal framework: Drugs and Cosmetics Act, 1940
- Age group: 4-60 years
- No prior testing required: Unlike earlier dengue vaccines
- Vector: Aedes aegypti mosquito
- 4 serotypes: DENV-1, 2, 3, 4
- Global distribution: 40+ countries, 32 million+ doses
- WHO prequalified: Ensures international quality standards